Loading...
14 bamlanivimab/etesevimab COVID-19 controlled studies, 5 RCTs
https://c19ly.com/meta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Gottlieb (RCT) 71%
0.29 [0.09-0.96]
hosp./ER
4/101
7/52
Improvement, RR [CI] Treatment Control Gottlieb (RCT) 80%
0.20 [0.03-1.56]
hosp./ER
1/37
7/52
Gottlieb (RCT) 75%
0.25 [0.03-1.92]
hosp./ER
1/30
7/52
Gottlieb (RCT) 56%
0.44 [0.10-1.98]
hosp./ER
2/34
7/52
Gottlieb (RCT) 92%
0.08 [0.00-1.39]
hosp./ER
0/31
7/52
Webb 80%
0.20 [0.03-1.46]
death
1/479
57/5,536
Webb 53%
0.47 [0.31-0.72]
hosp.
22/479
538/5,536
Webb 27%
0.73 [0.65-0.82]
hosp./ER
65/479
1,018/5,536
Dougan (DB RCT) 95%
0.05 [0.00-0.90]
death
0/518
9/517
Dougan (DB RCT) 70%
0.30 [0.16-0.59]
death/hosp.
11/518
36/517
Dougan (DB RCT) 11%
0.89 [0.82-0.97]
recov. time
518 (n)
517 (n)
Dougan (DB RCT) 67%
0.33 [0.25-0.45]
viral+
50/508
147/499
Cooper 45%
0.55 [0.07-3.99]
death
1/473
33/8,534
Cooper 58%
0.42 [0.10-1.72]
ICU
2/473
85/8,534
Cooper 5%
0.95 [0.69-1.30]
hosp.
37/473
703/8,534
Cooper -17%
1.17 [0.59-2.32]
death
11/2,427
33/8,534
Cooper 9%
0.91 [0.57-1.45]
ICU
22/2,427
85/8,534
Cooper 28%
0.72 [0.61-0.86]
hosp.
144/2,427
703/8,534
Rubin 44%
0.56 [0.07-4.33]
death
1/191
10/1,066
Rubin 65%
0.35 [0.12-0.94]
hosp.
16/191
121/1,065
Delasobera -119%
2.19 [0.23-20.9]
death
3/253
1/185
Delasobera 52%
0.48 [0.27-0.85]
hosp.
17/253
26/185
Delasobera 20%
0.80 [0.46-1.40]
progression
23/253
21/185
Dale 89%
0.11 [0.02-0.55]
death
5/56
9/19
Dale 86%
0.14 [0.04-0.52]
progression
6/56
10/19
Dale 54%
0.46 [0.08-1.97]
progression
6/56
3/19
Wilden 51%
0.49 [0.23-1.04]
hosp.
n/a
n/a
ACTIV-3/T.. (RCT) -100%
2.00 [0.69-5.83]
death
9/163
5/151
Bariola 67%
0.33 [0.10-1.01]
death
4/234
12/234
Bariola 64%
0.36 [0.20-0.61]
death/hosp.
16/234
45/234
Bariola 61%
0.39 [0.22-0.70]
hosp.
15/234
39/234
Ganesh 74%
0.26 [0.05-1.20]
death
2/1,789
8/1,832
Ganesh 49%
0.51 [0.24-1.09]
ICU
10/1,789
20/1,832
Ganesh 37%
0.63 [0.43-0.91]
hosp.
44/1,789
72/1,832
Chew (RCT) 25%
0.75 [0.26-2.10]
hosp.
6/159
8/158
Chew (RCT) 52%
0.48 [0.09-2.49]
hosp.
2/48
4/46
Chew (RCT) -1%
1.01 [0.26-3.93]
hosp.
4/111
4/112
Chew (RCT) -14%
1.14 [0.00-455]
recov. time
48 (n)
46 (n)
Chew (RCT) -17%
1.17 [0.98-1.40]
recov. time
111 (n)
112 (n)
Chew (RCT) 26%
0.74 [0.62-0.90]
viral load
48 (n)
46 (n)
Chew (RCT) 35%
0.65 [0.40-1.04]
viral load
111 (n)
112 (n)
Priest (PSM) 0%
1.00 [0.33-3.07]
death
6/379
6/379
Priest (PSM) -4%
1.04 [0.78-1.38]
hosp.
79/379
76/379
Priest (PSM) -5%
1.05 [0.73-1.52]
hosp./ER
379 (n)
379 (n)
Lilly (RCT) 57%
0.43 [0.28-0.67]
symp. case
483 (n)
482 (n)
Lilly (RCT) 80%
0.20 [0.08-0.47]
symp. case
150 (n)
149 (n)
bamlanivimab/etesevimab COVID-19 outcomes c19ly.com Jun 2022
Favors bamlanivimab/e..
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Submit
